We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Other Articles |

ACTIVITY OF A NEW ANTIMALARIAL AGENT, CHLOROQUINE (SN 7618) Statement Approved by the Board for Coordination of Malarial Studies

F. Loeb, M.D.; W. M. Clark, Ph.D.; G. R. Coatney, Ph.D.; L. T. Coggeshall, (MC); F. R. Dieuaide, M. C.; A. R. Dochez, M.D.; E. G. Hakansson, (MC); E. K. Marshall Jr., M.D.; C. S. Marvel, Ph.D.; O. R. McCoy, M. C.; James J. Sapero, (MC); W. H. Sebrell, M.D.; J. A. Shannon, M.D.; G. A. Carden Jr., M.D.
JAMA. 1946;130(16):1069-1070. doi:10.1001/jama.1946.02870160015006.
Text Size: A A A
Published online


An intensive exploration of the effects of SN 7618 on animals and man has been in progress during the past two years. This has included an evaluation of the activity of this compound in avian infections, a study of the pharmacology and toxicology in animals and man and finally of its potentialities as an antimalarial against vivax and falciparum infections in man. Included in the latter category are:

  1. Extensive studies on its prophylactic activity against domestic and Southwest Pacific strains of vivax malaria, on its curative activity against sporozoite-induced infections when administered alone and in combination with other compounds, and its suppressive activity.

  2. Extensive investigations in service installations of the potentialities of this drug for use in the termination of the acute attack and in the suppression of the disease.

The pharmacology of SN 7618 has been examined in fairly extensive experiments with mice, rats, dogs, monkeys and


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.